In comparison to anti-SARS-CoV-2 IgG, the detection of anti-SARS-CoV-2 IgM in COVID-19 patients was lower, being at 81%, 31%, 43%, and 9% IgM against RBD, N, S1, and S2, respectively. The gene discussed is CD40LG; the disease is COVID-19.